ResMed | RMD - Selling And Administration Expenses


ResMed reported $279.8M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Ansell USD 274.8M 7.6M Dec/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 84.55M 6.21M Mar/2026
Baxter International USD 728M 33M Mar/2026
Cochlear AUD 449.4M 214.45M Dec/2025
Cooper Companies USD 676.2M 303.1M Mar/2026
CSL USD 1.23B 498M Dec/2025
Dexcom USD 349.7M 49.8M Mar/2026
Edwards Lifesciences USD 522.2M 80.7M Mar/2026
Fisher Paykel Healthcare NZD 312.7M 27.2M Jun/2026
Globus Medical USD 297.77M 20.7M Mar/2026
Haemonetics USD 109.15M 7.54M Dec/2025
Idexx Laboratories USD 299.85M 24.18M Mar/2026
Inogen USD 43.77M 510K Jun/2024
Insulet USD 317.2M 14.2M Mar/2026
Integra LifeSciences USD 178.24M 21.79M Mar/2026
Intuitive Surgical USD 613.3M 73.8M Mar/2026
Medtronic 2.96B 9M Dec/2025
Philips EUR 1.18B 121M Mar/2026
Ramsay Health Care AUD 5.29B 3.2M Dec/2024
ResMed USD 279.8M 1.4M Mar/2026
Sigma Healthcare AUD 134.77M 9.73M Dec/2024
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Steris USD 351.8M 500K Mar/2026
Teleflex USD 226.01M 3.64M Mar/2026
Thermo Fisher Scientific USD 1.8B 179M Mar/2026